Aurobindo receives another approval from MCC South Africa

16108 Investors following Aurobindo Pharm. Share this News with them.

0

Like this story, share it with millions of investors on M3

Aurobindo receives another approval from MCC South Africa

Aurobindo receives yet another approval from MCC South Africa

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Aurobindo Pharma Q2 net profit up at Rs 54.6cr Aurobindo gets FDA nod for AIDS drug Aurobindo receives approval for Didanosine oral suspension Aurobindo joins hands with Gilead Sciences ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is delighted to announce that it has received another marketing authorization approval from Medicines Control Council (MCC) of South Africa. The Council has approved Stavudine tablets in 30mg and 40mg strengths.

South African market is highly regulated and very important in its Geographical sphere. Aurobindo by bagging this approval makes further inroads into this market as with Stavudine, the company has five of its ARV's products approved.

Stavudine is an antiviral agent of the nucleoside analog class (NRTI). The international brand name is Zerit and is marketed by Bristol Myers Squibb. Stavudine is used in combination with other NRTIs and NNRTIs class of drugs in HIV patients.

Stavudine enjoys a market of over 30 mio USD in South Africa.

Sourced From: Aurobindo Pharma Limited